Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN 24 FE vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy,Moderate acne vulgaris (in females ≥15 years who have onset of menarche and desire an oral contraceptive for contraception)
Prevention of pregnancy
One tablet (20 mcg ethinyl estradiol / 1 mg norethindrone acetate) orally once daily for 24 days, followed by 1 iron-containing placebo tablet (75 mg ferrous fumarate) orally once daily for 4 days.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Ethinyl estradiol: ~13 hours (range 7–20); norethindrone: ~8 hours (range 5–14). Half-life supports once-daily dosing; steady state achieved within 5–7 days.
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism in liver and gut wall, sulfation and glucuronidation. Norethindrone: primarily hepatic reduction and conjugation; metabolized via CYP3A4 and CYP2C9.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Ethinyl estradiol: 40% renal, 60% fecal; norethindrone: 40% renal, 60% fecal.
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Ethinyl estradiol: 98% bound to albumin and SHBG; norethindrone: 93% bound to albumin and SHBG.
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
Ethinyl estradiol: 2.3–4.0 L/kg; norethindrone: 3.0–4.5 L/kg. Indicates extensive tissue distribution.
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Ethinyl estradiol: ~45% (range 38–48%); norethindrone: ~65% (range 60–70%). First-pass metabolism reduces oral bioavailability.
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
No specific dose adjustment recommended; use with caution in patients with renal impairment. No GFR-based guidelines established.
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Contraindicated in patients with hepatic adenomas, acute hepatitis, or decompensated cirrhosis (Child-Pugh class B or C). No dose adjustment recommended in mild hepatic impairment (Child-Pugh class A) but use with caution.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Safety and efficacy established for use after menarche; dose same as adult: one active tablet daily for 24 days then one placebo tablet daily for 4 days. No weight-based dosing.
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
Not indicated for postmenopausal women; no specific dose adjustment recommended, but consider increased risk of thromboembolic events and cardiovascular disease in older women.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction, thromboembolism) from oral contraceptive use. Risk increases with age and number of cigarettes smoked, particularly in women >35 years. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thromboembolic disorders (e.g., DVT, PE, stroke, MI),Cigarette smoking (increases cardiovascular risk),Hypertension,Gallbladder disease,Hepatic neoplasia (liver tumors),Carbohydrate/lipid metabolism effects (hyperglycemia, hypertriglyceridemia),Headache (including migraine),Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Depression,Pregnancy and postpartum use,Lactation (may reduce milk production)
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenomas or carcinomas,Known or suspected hypersensitivity to any component of the product,Heavy smoking (>15 cigarettes/day) and age >35 years
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
No significant food interactions. Grapefruit juice may increase estrogen levels, but effect is minimal. Take with food if nausea occurs.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
LARIN 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on epidemiological data, but there is a small increased risk of cardiovascular defects. Second and third trimester exposure may cause fetal harm, including feminization of male fetuses (mild hypospadias) and potential for other teratogenic effects. Use is not recommended during pregnancy.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Combined hormonal contraceptives like LARIN 24 FE are generally not recommended during breastfeeding due to potential suppression of milk production and excretion of small amounts of hormones into breast milk. The M/P ratio is not well established; estrogens and progestins are present in milk at low concentrations. Use in lactating women should be avoided, especially in early postpartum period. Alternative contraception methods are preferred.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
No dose adjustments are applicable as LARIN 24 FE is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (increased clearance of steroids) are not relevant due to contraindication. Therapy should be discontinued immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
LARIN 24 FE is a combined hormonal contraceptive containing ethinyl estradiol and norethindrone. It uses a 24/4 regimen with 24 active pills and 4 iron-containing placebo pills. The iron (ferrous fumarate) in placebo pills is not contraceptive and serves to reduce iron-deficiency anemia risk. Prescribe for contraception, acne, or menstrual disorders. Monitor for VTE risk, especially in smokers over 35. Consider drug interactions with CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) which reduce efficacy. Breakthrough bleeding is common in the first 3 cycles.
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take one pill daily at the same time; missing pills increases pregnancy risk.,Active pills are light blue; placebo pills are brown and contain iron.,Use backup contraception for the first 7 days if starting after Day 5 of menstrual cycle.,If you miss two or more active pills, take the last missed pill and use backup contraception for 7 days.,Smoking while on this pill increases risk of serious cardiovascular side effects; do not smoke.,Report signs of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or vision changes.,Iron in placebo pills helps prevent anemia but does not provide contraception.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN 24 FE vs LARIN 1.5/30, answered by our medical review team.
LARIN 24 FE is a Combination Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN 24 FE and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN 24 FE is: One tablet (20 mcg ethinyl estradiol / 1 mg norethindrone acetate) orally once daily for 24 days, followed by 1 iron-containing placebo tablet (75 mg ferrous fumarate) orally once daily for 4 days.. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN 24 FE and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN 24 FE is classified as Category C. LARIN 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on epidemiological data, bu. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.